Skip Navigation

European Heart Journal 1995 16(Supplement I):33-48; doi:10.1093/eurheartj/16.suppl_I.33
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hamon, M.
Right arrow Articles by Bertrand, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hamon, M.
Right arrow Articles by Bertrand, M. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

Restenosis after coronary angioplasty

M. Hamon, C. Bauters, E. P. McFadden, N. Wernert, J. M. LaBlanche, B. Dupuis and M. E. Bertrand

Departments of Cardiology, Pharmacology and Pathology, University of Lille France

Correspondence: Dr Martial Hamon, Service de Cardiologie B et Hémodynamique, Hôpital Cardiologique, Boulevard du Professeur J Leclercq, 59037 Lille Cedex France

The major disadvantage of using percutaneous transluminal coronary angioplasty to treat patients with atherosclerotic coronary disease is the frequent occurrence of restenosis after an initially successful procedure. Studies in animals and histological observations in man have demonstrated that restenosis is characterized by neointimal hyperplasia due to smooth muscle cell proliferation and to the synthesis of extracellular matrix. Improvements in technology or pharmacological interventions have had no significant impact on the rate of restenosis. In spite of our increased understanding of the molecular mechanisms of restenosis, no effective treatment is available at the present time. Gene therapy, which has produced encouraging initial results in experimental models, may provide a solution in the medium term.

Key Words: Coronary angioplasty • restenosis • smooth muscle cell • balloon denudation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
G. Takemura, M. Nakagawa, H. Kanamori, S. Minatoguchi, and H. Fujiwara
Benefits of reperfusion beyond infarct size limitation
Cardiovasc Res, July 15, 2009; 83(2): 269 - 276.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.